Lord Herman Ouseley, Kick It Out founder, dies at 79
Kick It Out acknowledged Lord Ouseley's impact on football, crediting him with bringing about structural changes in the sport's fight against racism.
Lord Ouseley chaired Kick It Out for 25 years, beginning with its launch in 1993 as the campaign Let’s Kick Racism Out of Football. (Photo: Getty Images)
By EasternEyeOct 04, 2024
LORD Herman Ouseley, founder of the anti-discrimination charity Kick It Out, who worked to combat racism and discrimination in football, has died at the age of 79 after a short illness.
The news of his passing was announced by Kick It Out through its official X account.
"We are deeply saddened to hear about the passing of Lord Herman Ouseley after a short illness," the charity's statement read. "Lord Ouseley was a titan in tackling discrimination in football over the 25 years he was chair of Kick It Out, having founded Let's Kick Racism Out of Football in 1993."
We are deeply saddened to hear about the passing of Lord Herman Ouseley after a short illness.
Lord Ouseley was a titan in tackling discrimination in football over the 25 years he was chair of Kick It Out, having founded Let’s Kick Racism Out of Football in 1993. He was also a… pic.twitter.com/qWNZTcbDEJ
— Kick It Out (@kickitout) October 3, 2024
The statement also highlighted his role as a strong advocate for under-represented and disadvantaged communities, stating that he "will be sorely missed."
Kick It Out acknowledged Lord Ouseley's impact on football, crediting him with bringing about structural changes in the sport's fight against racism. "We owe him a huge debt of gratitude and vow to continue that legacy for the benefit of future generations."
The Football Association (FA), BBC reported, paid tribute to Lord Ouseley with a statement that read: "We are extremely saddened to hear about the passing of Lord Herman Ouseley.
"He was a trailblazer in English football, having the original vision for Kick It Out. He played a hugely inspirational role in tackling discrimination across our game."
Lord Ouseley chaired Kick It Out for 25 years, beginning with its launch in 1993 as the campaign Let’s Kick Racism Out of Football. According to The Guardian, he never received any financial compensation for his work with the charity.
The former footballer and anti-racism campaigner Troy Townsend paid tribute to Ouseley on X, saying: “No one told the truth like Herman told the truth. I owe you a debt of gratitude for everything you did for me, for football & society. May your pain be no more."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.